A clinical trial to understand the effect of hepcidin removal during dialysis on anaemia in End Stage Renal Disease patients

Hepcidin clearance in low flux hemodialysis, high flux hemodialysis, online hemodiafiltration and its effect on Erythropoietin Resistance Index in End Stage Renal Disease patients, A cohort study - NIL

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/074808

Enrollment

Registered

2024-10-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: Different modalities of Dialysis: Low Flux Dialysis,High flux hemodialysis and Online Hemodiafiltration for the period of 6 months Control Intervention1: Dialyser: Comparing different m

Eligibility

Inclusion criteria

Inclusion criteria: End Stage Renal Disease patients on Maintenance Hemodialysis above 18yrs of age Patients on maintenance hemodialysis for more than a year Patients who requires Erythropoietin Stimulating agents

Exclusion criteria

Exclusion criteria: Patients with malignancy disorders Critically ill patients Patients on treatment with hypoxia inducible factor stabilizers

Design outcomes

Primary

Measure	Time frame
-Serum Hepcidin ng/mL -ERI index (IU)/ bodyweight (kg)/ hemoglobin (g/dL) Timepoint: 0 and 6 months	—

Secondary

Measure	Time frame
â?¢Muscle mass index Kg/m2 â?¢QOL index Score Timepoint: 0 and 6 months	—

Countries

India

Contacts

Public ContactBargaviA

Manipal Hospitals Bangalore

bargavisrmc@gmail.com8861766644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026